Compatibility and physicochemical stability of ceftriaxone for injection admixed with pantoprazole sodium and ondansetron hydrochloride in different infusion solutions
Authors:
- 27 June 2025
- journal article
- Published by BMJ in European Journal of Hospital Pharmacy
- Vol. 33 (3) , 278-283
Abstract
The study aimed to analyse the physicochemical stability and compatibility of ceftriaxone sodium (CEF) (2mg/mL) with pantoprazole sodium (PAN) (0.08mg/mL) and ondansetron hydrochloride (OND) (0.008mg/mL) in different infusion solutions, specifically 0.9% sodium chloride injection (NS) and 5% dextrose injection (5D) under varied temperature conditions, including 2°C to 8°C, 25°C, and 37°C at different time intervals. This study involved determining the content of CEF, PAN and OND in infusion solutions, NS and 5D under varied temperature conditions, including 2°C to 8°C, 25°C, and 37°C at different time intervals using high performance liquid chromatography, visual description of solution mixture, pH measurement, osmolality, particulate matter (both visible and subvisible), as well as assessing the colour and clarity of the solution (measured by absorbance at 420 nm and % transmittance at 650 nm). No significant changes were observed in pH, osmolality, particulate matter, colour and clarity of admixture in NS up to 48 hours at all conditions. CEF, PAN and OND retained more than 90% of their initial concentration at 2°C to 8°C for 48 hours, 25°C for 8 hours, and 37°C for 8 hours. Also, no significant changes were observed in pH and osmolality of admixture in 5D up to 48 hours at all conditions. CEF, PAN and OND retained more than 90% of their initial concentration at 2°C to 8°C for 4 hours, 25°C for less than 2 hours, and 37°C for less than 2 hours. This study concludes that the physicochemical stability of a ternary admixture containing CEF, PAN and OND is diluent and temperature dependent. NS ensures acceptable stability, whereas 5D causes rapid degradation. For safety and efficacy, NS is recommended, with refrigerated storage preferred. Based on physicochemical stability data, the use of this parenteral admixture with 5D is not recommended.Keywords
This publication has 16 references indexed in Scilit:
- MS‐Compatible HPLC Method for Simultaneous Estimation of Ceftriaxone, Pantoprazole, and Ondansetron in Parenteral Formulations and AdmixturesSeparation Science Plus, 2025
- Physical compatibility of insulin aspart, lidocaine, alprostadil and vancomycin with individualised two-in-one parenteral nutrition used in the neonatal intensive care unitEuropean Journal of Hospital Pharmacy, 2025
- Cephalosporin Allergy: Current Understanding and Future ChallengesThe Journal of Allergy and Clinical Immunology: In Practice, 2019
- Stability and compatibility of ondansetron with haloperidol in parenteral admixturesEuropean Journal of Hospital Pharmacy, 2017
- Identification of a new isomer from a reversible isomerization of ceftriaxone in aqueous solutionJournal of Pharmaceutical and Biomedical Analysis, 2014
- Systematic review of physical and chemical compatibility of commonly used medications administered by continuous infusion in intensive care unitsCritical Care Medicine, 2010
- Basics in clinical nutrition: Drugs and nutritional admixturese-SPEN, the European e-Journal of Clinical Nutrition and Metabolism, 2009
- Errors in administration of parenteral drugs in intensive care units: multinational prospective studyBMJ, 2009
- Ethnographic study of incidence and severity of intravenous drug errorsBMJ, 2003
- Medication errors at the administration stage in an intensive care unitIntensive Care Medicine, 1999